Peptide vaccine

The registry record for Peptide vaccine does not describe the intervention beyond its name.

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Live record on ClinicalTrials.gov →

• Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)
• Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS
• Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
• No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• Males or females at least 18 years old

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.